FI951218A7 - Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikoles trolin pitoisuuksien pienentämiseksi veressä - Google Patents

Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikoles trolin pitoisuuksien pienentämiseksi veressä Download PDF

Info

Publication number
FI951218A7
FI951218A7 FI951218A FI951218A FI951218A7 FI 951218 A7 FI951218 A7 FI 951218A7 FI 951218 A FI951218 A FI 951218A FI 951218 A FI951218 A FI 951218A FI 951218 A7 FI951218 A7 FI 951218A7
Authority
FI
Finland
Prior art keywords
blood
low
density lipoprotein
reducing total
cholesterol
Prior art date
Application number
FI951218A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI951218L (fi
FI951218A0 (fi
Inventor
Steven L Nissen
Original Assignee
Iowa State Univ Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI951218(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State Univ Research filed Critical Iowa State Univ Research
Publication of FI951218L publication Critical patent/FI951218L/fi
Publication of FI951218A0 publication Critical patent/FI951218A0/fi
Publication of FI951218A7 publication Critical patent/FI951218A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI951218A 1992-09-16 1993-09-15 Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikoles trolin pitoisuuksien pienentämiseksi veressä FI951218A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (3)

Publication Number Publication Date
FI951218L FI951218L (fi) 1995-03-15
FI951218A0 FI951218A0 (fi) 1995-03-15
FI951218A7 true FI951218A7 (fi) 1995-03-15

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951218A FI951218A7 (fi) 1992-09-16 1993-09-15 Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikoles trolin pitoisuuksien pienentämiseksi veressä

Country Status (12)

Country Link
US (1) US5360613A (enExample)
EP (1) EP0660706B1 (enExample)
JP (1) JP3148243B2 (enExample)
AU (1) AU673002B2 (enExample)
BR (1) BR9307035A (enExample)
CA (1) CA2142314C (enExample)
DE (1) DE69327468T2 (enExample)
ES (1) ES2142353T3 (enExample)
FI (1) FI951218A7 (enExample)
NO (1) NO951000L (enExample)
NZ (1) NZ256300A (enExample)
WO (1) WO1994006417A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2000043017A1 (en) * 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
WO2002094255A1 (de) * 2001-05-18 2002-11-28 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
WO2007075605A2 (en) 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
PT2381784T (pt) * 2008-12-09 2018-10-30 Metabolic Tech Inc Intervenção nutricional para melhorar função e força muscular
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
MX2012008785A (es) 2010-01-29 2012-08-17 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
BR112014003434A2 (pt) * 2011-08-15 2017-03-01 Abbott Lab processo para produção de hmb e seus sais
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
WO2014040067A1 (en) 2012-09-10 2014-03-13 Metabolic Technologies, Inc. Composition of hmb and atp and methods of use
EP3122348B1 (en) 2014-03-27 2020-05-27 Winterfield, Roland, W. Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
JP7114458B2 (ja) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド 軟組織外傷からの回復を増強するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
KR20180088809A (ko) 2015-11-19 2018-08-07 가부시키가이샤 오츠카 세이야쿠 코죠 3-히드록시이소발레르산의 1가 양이온염의 결정 및 그 결정의 제조 방법
BR112018014920A2 (en) 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
EP3476825A4 (en) 2016-06-24 2020-02-26 Kyowa Hakko Bio Co., Ltd. CRYSTAL OF BETA-HYDROXY-BETA-METHYLBUTTERIC ACID-AMINO ACID SALT AND PRODUCTION METHOD THEREFOR
PL3528801T3 (pl) 2016-10-21 2025-02-03 Metabolic Technologies, LLC Kompozycje i sposoby zastosowania beta-hydroksy-beta-metylomaślanu (hmb) i probiotyków

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
FI951218L (fi) 1995-03-15
EP0660706B1 (en) 1999-12-29
JPH08501777A (ja) 1996-02-27
FI951218A0 (fi) 1995-03-15
US5360613A (en) 1994-11-01
AU673002B2 (en) 1996-10-24
CA2142314A1 (en) 1994-03-31
WO1994006417A1 (en) 1994-03-31
NO951000D0 (no) 1995-03-15
BR9307035A (pt) 1999-06-29
DE69327468D1 (de) 2000-02-03
NO951000L (no) 1995-03-15
NZ256300A (en) 1997-06-24
DE69327468T2 (de) 2000-05-11
CA2142314C (en) 1999-06-01
EP0660706A4 (enExample) 1995-07-26
EP0660706A1 (en) 1995-07-05
AU4922593A (en) 1994-04-12
ES2142353T3 (es) 2000-04-16
JP3148243B2 (ja) 2001-03-19

Similar Documents

Publication Publication Date Title
FI951218L (fi) Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
FI943249A0 (fi) Menetelmä vastaanottimen ohjaamiseksi ja vastaanotMenetelmä vastaanottimen ohjaamiseksi ja vastaanotin in
NO933966L (no) Stoff for senkning av hoeyt kolesterolnivaa i serum og fremgangsmaate for fremstilling av stoffet
EE03399B1 (et) Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
FI955727L (fi) Menetelmä ja laite liposomien valmistamiseksi
FI930942L (fi) Menetelmä ja kytkentä suodatintyypin vaihtamiseksi
DE69524402D1 (de) Arzneiabgabevorrichtung und deren konstruktionsmethode
FI951305L (fi) Lääketieteellinen materiaali ja menetelmä sen valmistamiseksi
FI972260L (fi) Laite ja menetelmä pintojen käsittelemiseksi
FI954861A0 (fi) Ripustettu vaunu ja kiskoon liittyvä menetelmä
FI954168A7 (fi) Jauhantamenetelmä vaakasuoran myllyn avulla ja vaakasuora mylly
FI944604A7 (fi) Tulenkestävä paneeli ja menetelmä sen valmistamiseksi
FI971355A7 (fi) Menetelmä ja järjestely siirtojärjestelmässä
FI972235L (fi) Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin hoidossa ja ehkäisyssä
FI962538L (fi) Menetelmä ja laite nesteiden käsittelemiseksi
FI960835A7 (fi) Laite ja menetelmä materiaalien hienontamiseksi
FI951060A7 (fi) Formulaatioita ja hoitomenetelmiä
FI943895L (fi) Paperinvalmistusmenetelmä ja menetelmän toteuttava laitteisto
FI952504L (fi) Väkevöimismenetelmä ja välineet sitä varten
FI964267A7 (fi) Porfosyaniini ja CNC-laajennetut porfyriinit
FI951228L (fi) Menetelmä ja laite nauhojen valssausta varten
FI941246A7 (fi) Menetelmä ja laite jännitelähteiden regeneroimiseksi ensiöelementtien muodossa
FI943188L (fi) Nestekidekopolyesteri-imidit ja menetelmä niiden valmistamiseksi
FI942298A0 (fi) Menetelmä ja sovitelma tilaelementtien siirtämiseksi